Freshpet (FRPT)

NASDAQConsumer StaplesPackaged FoodsSnapshot 2026-10-23

$64.12-4.30%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Freshpet’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

-2.0%

+10% or more+5%0%−5%−10% or less

1.86 → 1.82 EPS · FY ending Dec 31, 2027 · 7 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 6 to 7; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	312.81M
EPS	—	0.544
Annual ending 2026-12-31
Revenue	—	1.23B
EPS	—	1.986
Annual ending 2027-12-31
Revenue	—	1.33B
EPS	—	1.821

Management figures unavailable.

What the Thesis Depends On

5 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Capital expenditures near $150 million in 2026	Management guides disciplined capital spending near $150M with positive cash flow.	Intact	Capital expenditures exceed $175 million in 2026	Capital expenditures: $29.725M FY2026-Q2; GAAP. Published target: ~$150 million. Target period ends 2026-12-31; this observation covers 2026-Q2. Source published Aug 5, 202629,725,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. Management maintained guidance for positive free cash flow with capital expenditures around $150 million for 2026, down from $175 million in 2025. The trajectory shows disciplined capex management supporting positive cash flow. Delivery assessment Oct 24, 2026
Gross margin stays near 40.5% in 2026-Q1	A primary condition in Freshpet's published investment case. The stated target is >= 40.5%.	Intact	Gross margin falls below 39%	Gross margin: 42.11% FY2026-Q2; GAAP. Published target: >= 40.5%. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 5, 202642.113702 percent · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: f494419e-2aac-47ab-81dd-e5276465780e. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. Adjusted Gross Margin improved from 46.9% in 2025-Q2 to 48.6% in 2026-Q2. Management updated long-term guidance to at least 49% for 2027 from prior 48%. The trajectory shows steady margin improvement and raised targets. Delivery assessment Oct 24, 2026
Leadership transitions do not disrupt strategy	A supporting condition in Freshpet's published investment case. The stated target is Stable leadership with smooth transitions.	Improving	Leadership changes cause strategic disruption or execution failure	Qualitative: Smooth transition confirmed (Morris retired, Baty promoted) June 2026: Co-founder Scott Morris retired. October 2026: Nicola Baty promoted to President. No signs of strategic disruption. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Newly stated in 2026-Q1 period. Management announced strategic leadership hires in finance and supply chain to support growth and operational goals. No quantitative financial impact yet reported; this is an early-stage priority. Delivery assessment Oct 24, 2026
Net income improves to at least $48.5 million in 2026-Q1	Net income rose from a loss to $48.5M in 2026-Q1.	Intact	Net income falls below $30 million in 2026-Q1	Net income: $19.488M FY2026-Q2; GAAP. Published target: >= $48.5 million. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 5, 202619,488,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: f494419e-2aac-47ab-81dd-e5276465780e. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. Net income increased from $16.4 million in 2025-Q2 to $19.5 million in 2026-Q2. Full year 2025 net income was $139.1 million, up from $46.9 million prior year. The trajectory shows consistent improvement in profitability. Delivery assessment Oct 24, 2026
Net sales reach at least $297.6 million in 2026-Q1	A primary condition in Freshpet's published investment case. The stated target is >= $297.6 million.	Intact	Net sales fall below $285 million in 2026-Q1	Revenue: $305.587M FY2026-Q2; GAAP. Published target: >= $297.6 million. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 5, 2026305,587,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: f494419e-2aac-47ab-81dd-e5276465780e. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. Revenue grew from $264.7 million in 2025-Q2 to $305.6 million in 2026-Q2, a 15.5% increase. Management raised 2026 net sales growth guidance to 10%-12% from prior 8%-11%. The trajectory is delivering with accelerating growth and raised guidance. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$1.82

$1.84 → $1.82 · observed estimates

FY2027 revenue$1.33B

$1.32B → $1.33B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$1.84	$1,319,004,719	5 / 14
2026-07-25	$1.79	$1,318,115,680	5 / 18
2026-07-26	$1.79	$1,318,115,680	5 / 18
2026-07-27	$1.83	$1,317,936,960	6 / 14
2026-07-28	$1.83	$1,317,936,960	6 / 14
2026-07-29	$1.83	$1,317,936,960	6 / 14
2026-07-30	$1.79	$1,318,266,210	5 / 18
2026-07-31	$1.79	$1,318,266,210	5 / 18
2026-08-01	$1.84	$1,318,151,710	6 / 14
2026-08-02	$1.79	$1,318,266,210	5 / 18
2026-08-03	$1.79	$1,318,266,210	5 / 18
2026-08-04	$1.79	$1,318,266,210	5 / 18
2026-08-05	$1.79	$1,318,266,210	5 / 18
2026-08-06	$1.79	$1,318,266,210	5 / 18
2026-08-07	$1.81	$1,326,622,934	6 / 14
2026-08-08	Unavailable	$1,325,705,000	4 / 17
2026-08-09	Unavailable	$1,325,705,000	4 / 17
2026-08-10	Unavailable	$1,325,705,000	4 / 17
2026-08-11	$1.81	$1,326,622,934	6 / 14
2026-08-12	$1.96	$1,327,782,110	6 / 18
2026-08-13	$1.81	$1,326,622,934	6 / 14
2026-08-14	$1.81	$1,326,622,934	6 / 14
2026-08-15	$1.81	$1,326,622,934	6 / 14
2026-08-16	$1.81	$1,326,622,934	6 / 14
2026-08-17	$1.81	$1,326,622,934	6 / 14
2026-08-18	$1.81	$1,326,622,934	6 / 14
2026-08-19	$1.81	$1,326,622,934	6 / 14
2026-08-20	$1.86	$1,327,638,859	6 / 14
2026-08-21	$1.86	$1,327,638,859	6 / 14
2026-08-22	$1.86	$1,327,638,859	6 / 14
2026-08-23	$1.86	$1,327,638,859	6 / 14
2026-08-24	$1.86	$1,327,638,859	6 / 14
2026-08-25	$1.86	$1,328,594,443	6 / 14
2026-08-26	$1.86	$1,328,594,443	6 / 14
2026-08-27	$1.86	$1,328,594,443	6 / 14
2026-08-28	$1.86	$1,328,594,443	6 / 14
2026-08-29	$1.86	$1,328,594,443	6 / 14
2026-08-30	$1.86	$1,328,594,443	6 / 14
2026-08-31	$1.86	$1,328,594,443	6 / 14
2026-09-01	$1.86	$1,328,594,443	6 / 14
2026-09-02	$1.86	$1,328,594,443	6 / 14
2026-09-03	$1.86	$1,328,594,443	6 / 14
2026-09-04	$1.86	$1,328,594,443	6 / 14
2026-09-05	$1.86	$1,328,594,443	6 / 14
2026-09-06	$1.86	$1,328,594,443	6 / 14
2026-09-07	$1.86	$1,328,594,443	6 / 14
2026-09-08	$1.86	$1,328,594,443	6 / 14
2026-09-09	$1.86	$1,328,594,443	6 / 14
2026-09-10	$1.86	$1,328,594,443	6 / 14
2026-09-11	$1.86	$1,328,594,443	6 / 14
2026-09-12	$1.86	$1,328,594,443	6 / 14
2026-09-13	$1.86	$1,328,594,443	6 / 14
2026-09-14	$1.86	$1,328,594,443	6 / 14
2026-09-15	$1.86	$1,328,594,443	6 / 14
2026-09-16	$1.86	$1,328,594,443	6 / 14
2026-09-17	$1.86	$1,328,594,443	6 / 14
2026-09-18	$1.86	$1,328,594,443	6 / 14
2026-09-19	$1.86	$1,329,310,756	6 / 14
2026-09-20	$1.86	$1,329,310,756	6 / 14
2026-09-21	$1.86	$1,329,310,756	6 / 14
2026-09-22	$1.86	$1,329,310,756	6 / 14
2026-09-23	$1.86	$1,329,310,756	6 / 14
2026-09-24	$1.86	$1,329,310,756	6 / 14
2026-09-25	$1.77	$1,329,310,756	6 / 14
2026-09-26	$1.77	$1,329,310,756	6 / 14
2026-09-27	$1.77	$1,329,310,756	6 / 14
2026-09-28	$1.77	$1,329,310,756	6 / 14
2026-09-29	$1.77	$1,329,310,756	6 / 14
2026-09-30	$1.77	$1,329,310,756	6 / 14
2026-10-01	$1.77	$1,329,310,756	6 / 14
2026-10-02	$1.77	$1,328,733,653	7 / 15
2026-10-03	$1.77	$1,328,733,653	7 / 15
2026-10-04	$1.77	$1,328,733,653	7 / 15
2026-10-05	$1.77	$1,328,733,653	7 / 15
2026-10-06	$1.77	$1,328,733,653	7 / 15
2026-10-07	$1.77	$1,328,733,653	7 / 15
2026-10-08	$1.77	$1,328,733,653	7 / 15
2026-10-09	$1.77	$1,328,733,653	7 / 15
2026-10-10	$1.77	$1,328,733,653	7 / 15
2026-10-11	$1.77	$1,328,733,653	7 / 15
2026-10-12	$1.77	$1,328,733,653	7 / 15
2026-10-13	$1.78	$1,329,100,659	7 / 15
2026-10-14	$1.83	$1,329,100,677	7 / 15
2026-10-15	$1.83	$1,329,100,677	7 / 15
2026-10-16	$1.83	$1,329,712,442	7 / 15
2026-10-17	$1.83	$1,329,712,442	7 / 15
2026-10-18	$1.83	$1,329,712,442	7 / 15
2026-10-19	$1.83	$1,329,712,442	7 / 15
2026-10-20	$1.83	$1,329,712,442	7 / 15
2026-10-21	$1.83	$1,329,712,442	7 / 15
2026-10-22	$1.82	$1,329,947,736	7 / 15
2026-10-23	$1.82	$1,329,947,736	7 / 15
2026-10-24	$1.82	$1,329,947,736	7 / 15

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	15	4
2026-06-01	14	3
2026-07-01	14	3
2026-08-01	14	4
2026-09-01	13	4
2026-10-01	13	5

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 13 Buy / Strong Buy · 5 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades2 maintains

Recent actions · Sep 25–Oct 24 · 2 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Deutsche BankOct 21 · prior Aug 6

$70.00 → $67.00-4.3%

$0$38.50$77.00

0 raises · 1 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Capital expenditures near $150 million in 2026Capital expenditures: $29.725M
Gross margin stays near 40.5% in 2026-Q1Gross margin: 42.11%
Net income improves to at least $48.5 million in 2026-Q1Net income: $19.488M
Net sales reach at least $297.6 million in 2026-Q1Revenue: $305.587M

Next proof point

Nov 4, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 5 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.5%Typical daily move · historical

Downside history

-44.6%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Freshpet outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

FRPT is a growth-oriented consumer staples business, with a multi-year view supported by rising sales and net income. The thesis is intact, but the recent signal has shifted from mildly favorable to mixed, and risk is elevated.

What's priced into Freshpet

FRPT trades at a substantial premium to peers, while the evidence rates overall value as neutral and the valuation model has low confidence. The expectations gap is modest, and the premium is not matched by a broader combination of weak fundamentals and market turbulence in the snapshot.

What the fundamentals likely do

Near-term results show sales and net income growth, and management raised 2026 sales growth guidance; adjusted gross margin also improved, though its status is mixed. The recent earnings event was positive, but a history of a deep miss and a trend of declining earnings surprises temper the outlook.

What Freshpet hinges on

The multi-year thesis depends on continued sales growth, better margins, and stronger profitability. Near term, a guidance cut after the recent increase would damage credibility, while weakening jobs data could weigh on consumer staples; continued strong results and guidance from sector peers could support the backdrop.